L3VLUP
ProSign in

GUTS · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GUTSLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GUTS
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterGUTSLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 2022none listed holders, n.a.24 holders, $35.3bn
Q2 2022none listed holders, n.a.33 holders, $42.7bn
Q3 2022none listed holders, n.a.31 holders, $43.4bn
Q4 2022none listed holders, n.a.31 holders, $46.6bn
Q1 2023none listed holders, n.a.33 holders, $44.3bn
Q2 2023none listed holders, n.a.37 holders, $59.6bn
Q3 2023none listed holders, n.a.44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 20242 holders, $33m41 holders, $95.3bn
Q2 20242 holders, $19m43 holders, $110bn
Q3 20241 holders, $11m45 holders, $107bn
Q4 20241 holders, $8.8m46 holders, $93.9bn
Q1 20251 holders, $5.1m42 holders, $98.4bn
Q2 20251 holders, $6.9m43 holders, $93.2bn
Q3 20252 holders, $16m39 holders, $86.7bn
Q4 20252 holders, $21m41 holders, $123bn
Q1 20261 holders, $1.8m39 holders, $106bn
Q2 20261 holders, $3.2m44 holders, $132bn
GUTS

Fractyl Health Inc

Holders
1
Reported value
$1.8m
Buyers
0
Sellers
21

Breadth -21 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only GUTS (1)

Maverick Capital Ltd

Only LLY (39)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, and 14 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →